Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Intracerebral Stem Cells (CTX0E03) in Subjects With Disability Following an Ischemic Stroke

Trial Profile

A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Intracerebral Stem Cells (CTX0E03) in Subjects With Disability Following an Ischemic Stroke

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2019

At a glance

  • Drugs ReN 001 (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms PISCES III
  • Sponsors ReNeuron
  • Most Recent Events

    • 24 Jan 2019 According to a ReNeuron media release, Sean I. Savitz MD (Professor and Director of the Institute for Stroke and Cerebrovascular Disease at the University of Texas Health Science Center at Houston (UTHealth)) is the global principal investigator for this study.
    • 24 Jan 2019 According to a ReNeuron media release, top-line results from this study are expected in early 2020.
    • 24 Jan 2019 According to a ReNeuron media release, the first patient has been treated in this phase IIb trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top